Higher-risk MDS and newly diagnosed AML What are the latest developments from EHA 2022

touchCONGRESS for touchONCOLOGY Listen to Dr Esther Oliva (Italy) review key data presented at the EHA 2022 Hybrid Congress on recent developments in the treatment of higher-risk MDS and newly diagnosed AML; she offers her expert insights on their potential impact on future clinical practice, alongside those from Prof. Michael Heuser (Germany) and Dr Yishai Ofran (Israel).  OVERVIEW Data review with Dr Oliva (0:00) Expert interviews with Prof. Heuser, Dr Ofran and Dr Oliva, answering the questions below INTERVIEW QUESTIONS Based on data presented at EHA 2022, which emerging treatments are most likely to impact future clinical practice for patients with HR-MDS? (30:08) What do the latest data presented at EHA 2022 tell us about the clinical relevance of TP53 mutation in HR-MDS and newly diagnosed AML? (35:47) To what extent will lower-intensity treatment regimens improve patient outcomes in newly diagnosed AML ineligible for intensive chemotherapy? Which of the emerging regimens do you think will be most important? (42:06) Based on the latest research presented at EHA 2022, which prognostic tools and biomarkers do you consider most promising to support treatment decisions in HR-MDS or newly diagnosed AML? (49:55) This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. For further information visit our website: https://touchoncology.com/education/MDS-AML-EHA2022-touchcongress/